Abstract
DNA methylation (DNAm) has been reported to be associated with many diseases and mortality. We hypothesized that the integration of DNAm with clinical risk factors would improve mortality prediction.We performed an epigenome-wide association study of whole blood DNAm in relation to mortality in 15 cohorts (n=15,013). During a mean follow-up of 10 years, there were 4314 deaths from all-causes including 1235 cardiovascular disease (CVD) deaths and 868 cancer deaths. Ancestry-stratified meta-analysis of all-cause mortality identified 163 CpGs in European ancestry (EA) and 17 in African ancestry (AA) participants at P<1x10-7, of which 41 (EA) and 16 (AA) were also associated with CVD death, and 15 (EA) and 9 (AA) with cancer death. We built DNAm-based prediction models for all-cause mortality that predicted mortality risk independent of clinical risk factors. The mortality prediction model trained by integrating DNAm with clinical risk factors showed a substantial improvement in prediction of cancer death with 11% and 5% increase in the C-index in internal and external replications, compared with the model trained by clinical risk factors alone. Mendelian randomization identified 15 CpGs in relation to longevity, CVD, or cancer risk. For example, cg06885782 (in KCNQ4) was positively associated with risk for prostate cancer (Beta=1.2, PMR=4.1x10-4), and negatively associated with longevity (Beta=-1.9, PMR=0.02). Pathway analysis revealed that genes associated with mortality-related CpGs are enriched for immune and cancer related pathways. We identified replicable DNAm signatures of mortality and demonstrated the potential utility of CpGs as informative biomarkers for prediction of mortality risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Framingham Heart Study is funded by National Institutes of Health contract N01 HC 25195 and HHSN268201500001I. The laboratory work for this investigation was funded by the Division of Intramural Research National Heart Lung and Blood Institute National Institutes of Health. The analytical component of this project was funded by the Division of Intramural Research National Heart Lung and Blood Institute and the Center for Information Technology National Institutes of Health Bethesda MD. The Cardiovascular Health Study is supported by NHLBI contracts HHSN268201200036C – HHSN268200800007C&– HHSN268201800001C– N01HC55222– N01HC8507– N01HC85080– N01HC85081– N01HC85082– N01HC85083– N01HC85086– and NHLBI grants U01HL080295– U01HL130114– K08HL116640– R01HL087652– R01HL092111– R01HL103612– R01HL105756– R01HL103612– R01HL111089– R01HL116747 and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke NINDS. Additional support was provided through R01AG023629 from the National Institute on Aging NIA Merck Foundation Society of Epidemiologic Research as well as Laughlin Family Alpha Phi Foundation and Locke Charitable Foundation. A full list of principal CHS investigators and institutions can be found at chs–nhlbi.org The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences CTSI grant UL1TR000124 and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center DRC grant DK063491 to the Southern California Diabetes Endocrinology Research Center. Infrastructure for the CHARGE Consortium is supported in part by the National Heart Lung and Blood Institute grant R01HL105756. The DTR study was supported by The Danish Council for Independent Research Medical Sciences DFF–6110–00016 the European Unions Seventh Framework Programme FP7 2007–2011 under grant Agreement No 259679 and The Danish National Program for Research Infrastructure 2007 09[ndash]063256). The WHI program is funded by the National Heart Lung and Blood Institute National Institutes of Health US Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C; HHSN268201600002C; HHSN268201600003C; and HHSN268201600004C. Work in WHI was NIEHS supported by R01–ES020836 EAW– AB– and LH. Phenotype collection in the Lothian Birth Cohort 1921 was supported by the UKs Biotechnology and Biological Sciences Research Council BBSRC – The Royal Society and The Chief Scientist Office of the Scottish Government. Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK The Disconnected Mind project. Methylation typing was supported by Centre for Cognitive Ageing and Cognitive Epidemiology Pilot Fund award – Age UK – The Wellcome Trust Institutional Strategic Support Fund – The University of Edinburgh – and The University of Queensland. IJD is a member of the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology CCACE which is supported by funding from the BBSRC – the Medical Research Council – MRC and the University of Edinburgh as part of the cross council Lifelong Health and Wellbeing initiative MR–K026992–1. WDH is supported by a grant from Age UK Disconnected Mind Project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study included participants from 12 population-based cohorts studies including the Atherosclerosis Risk in Communities ARIC Study the Cardiovascular Health Study CHS the Danish Twin Register sample DTR the Epidemiologische Studie zu Chancen der Verhütung Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung ESTHER the Framingham Heart Study FHS the Invecchiare in Chianti InCHIANTI Study the Cooperative Health Research in the Region of Augsburg KORA F4 the Lothian Birth Cohorts of 1921 LBC1921 and 1936 LBC1936 the Normative Aging Study NAS the Rotterdam Study RS and Womens Health Initiative WHI. All of the 12 studies were approved by their institutional review committees see details in Additional file 1. All study participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵(tianxiao.huan{at}umassmed.edu), (nguy2295{at}umn.edu), (elena.colicino{at}mssm.edu), (c.ochoarosales{at}erasmusmc.nl), (David.Hill{at}ed.ac.uk), (jeco{at}uw.edu), (msoerensen{at}health.sdu.dk), (y.zhang{at}Dkfz-Heidelberg.de), (baldassa{at}email.unc.edu), (mohamed.elhadad{at}helmholtz-muenchen.de), (tanakato{at}mail.nih.gov), (y-zheng{at}northwestern.edu), (ad3531{at}cumc.columbia.edu), (dephs1042{at}gmail.com), (jiantao.ma{at}tufts.edu), (chenyao.bioinfor{at}gmail.com), (liuc{at}bu.edu), (hwangs2{at}nhlbi.nih.gov), (roby.joehanes{at}nih.gov), (Myriam.Fornage{at}uth.tmc.edu), (jan.bressler{at}uth.tmc.edu), (j.vanmeurs{at}erasmusmc.nl), (bdebrabant{at}health.sdu.dk), (jmengel-from{at}health.sdu.dk), (JHjelmborg{at}health.sdu.dk), (KChristensen{at}health.sdu.dk), (pantel.vokonas{at}va.gov), (joel{at}hsph.harvard.edu), (sagharib{at}u.washington.edu), (nsotoo{at}uw.edu), (csitlani{at}uw.edu), (sonja.kunze{at}helmholtz-muenchen.de), (christian.gieger{at}helmholtz-muenchen.de), (peters{at}helmholtz-muenchen.de), (waldenberger{at}helmholtz-muenchen.de), (iand{at}exseed.ed.ac.uk), (FerrucciLu{at}grc.nia.nih.gov), (yishu.qu{at}northwestern.edu), (p-greenland{at}northwestern.edu), (dlj{at}northwestern.edu), (l-hou{at}northwestern.edu), (stefania1.bandinelli{at}uslcentro.toscana.it), (trudy.voortman{at}erasmusmc.nl), (h.brenner{at}Dkfz-Heidelberg.de), (ab4303{at}cumc.columbia.edu), (eric_whitsel{at}med.unc.edu), (panko001{at}umn.edu), (levyd{at}nhlbi.nih.gov)
Data Availability
The DNA methylation data and phenotype data are available in dbGaP for some of the cohorts in this study (https://www.ncbi.nlm.nih.gov/gap/) including FHS (accession number phs000724.v5.p10) and WHI (accession number phs000200.v12.p3). For LBC, data are available in the European Genome-phenome Archive (https://www.ebi.ac.uk/ega/home), under accession number EGAS00001000910. For the other cohorts including ARIC, CHS, NAS, InCHIANTi, KORA, ESTHER, Danish, RS and CARDIA, the data are available on request by contacting with the principal investigators of each cohort.
